Risk of heart failure up in ALVSD patients with diabetes

July 27, 2018

(HealthDay)—For patients with asymptomatic left ventricular systolic dysfunction (ALVSD), those with diabetes have increased risk of heart failure development and hospitalization, according to a study published in the June issue of Diabetes Care.

Rasmus Rørth, M.D., from the University of Glasgow in the United Kingdom, and colleagues examined the development of symptomatic heart failure, heart failure hospitalization, and according to baseline diabetes status in patients from the prevention arm of the Studies of Left Ventricular Dysfunction.

Overall, 15 percent of the 4,223 eligible participants had diabetes at baseline. The researchers found that 24 percent of the 3,567 patients without diabetes at baseline developed heart failure, compared with 33 percent of the 647 patients with diabetes during a median follow-up of 36 months. Patients with diabetes had an elevated risk for development of heart failure, heart failure hospitalization, and the composite outcome of development of heart failure or cardiovascular death (hazard ratios, 1.53, 2.04, and 1.48, respectively), in unadjusted analyses. Diabetes status did not modify the effect of enalapril on outcomes.

"In patients with ALVSD, is associated with an increased risk of developing heart failure, heart failure hospitalization and cardiovascular death," the authors write. "This information might help in the development of strategies to prevent the transition from ALVSD to overt ."

Explore further: In LVSD, diabetes tied to higher risk of heart failure

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

In LVSD, diabetes tied to higher risk of heart failure

April 20, 2018
(HealthDay)—In patients with asymptomatic left ventricular systolic dysfunction, diabetes is associated with an increased risk of developing heart failure, according to a study published online April 6 in Diabetes Care.

Elevated NT-proBNP found to up cardiovascular risk in T2DM

June 15, 2018
(HealthDay)—Elevated baseline N-terminal B-type natriuretic peptide (NT-proBNP) is independently associated with development of major cardiovascular (CV) events, in particular hospitalization for heart failure, according ...

Impact of T2DM meds on heart failure hospitalization explored

January 19, 2016
(HealthDay)—For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with ...

Risk conferred by T2D modified by HbA1c in heart failure

October 12, 2017
(HealthDay)—For patients with heart failure, the risks conferred by type 2 diabetes (T2D) can be stratified by glycemic control and drug treatments, according to a study published online Oct. 11 in JACC: Heart Failure.

Death rates from heart failure higher for women than men

July 16, 2018
Death rates from heart failure are higher for women than men, and hospitalization rates have increased in women while declining in men, found a study from the University of Ottawa Heart Institute published in CMAJ (Canadian ...

Diabetes may have important effects in patients with acute heart failure

June 26, 2017
Researchers have found that patients with acute heart failure and diabetes, compared with those without diabetes, have distinct markers related to inflammation, cardiovascular function, and kidney health.

Recommended for you

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.